Literature DB >> 12562696

Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species.

Dimitrios P Kontoyiannis1, Russell E Lewis, Nir Osherov, Nathaniel D Albert, Gregory S May.   

Abstract

Work in Saccharomyces cerevisiae and Cryptococcus neoformans suggests that caspofungin could interact with the calcineurin pathway. We examined the in vitro interaction of caspofungin with calcineurin inhibitors (FK506, cyclosporin, FK520 and L685,818) and the TOR inhibitor rapamycin in 13 isolates of Aspergillus species. Caspofungin activity was enhanced by calcineurin/TOR inhibitors for all Aspergillus isolates studied. Further investigation of this pathway is warranted.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12562696     DOI： 10.1093/jac/dkg090

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  40 in total

Review 1.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients.

Authors:  William J Steinbach; Nina Singh; Jackie L Miller; Daniel K Benjamin; Wiley A Schell; Joseph Heitman; John R Perfect
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

Review 3.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

4.  Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis.

Authors:  Dimitrios P Kontoyiannis; Russell E Lewis; Barbara D Alexander; Olivier Lortholary; Françoise Dromer; Krishan L Gupta; George T John; Ramon Del Busto; Goran B Klintmalm; Jyoti Somani; G Marshall Lyon; Kenneth Pursell; Valentina Stosor; Patricia Munoz; Ajit P Limaye; Andre C Kalil; Timothy L Pruett; Julia Garcia-Diaz; Atul Humar; Sally Houston; Andrew A House; Dannah Wray; Susan Orloff; Lorraine A Dowdy; Robert A Fisher; Joseph Heitman; Nathaniel D Albert; Marilyn M Wagener; Nina Singh
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

5.  In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.

Authors:  Eric Dannaoui; Patrick Schwarz; Olivier Lortholary
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

Review 6.  Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.

Authors:  Leah E Cowen; William J Steinbach
Journal:  Eukaryot Cell       Date:  2008-03-28

7.  Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways.

Authors:  Nathan P Wiederhold; Dimitrios P Kontoyiannis; Randall A Prince; Russell E Lewis
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 8.  Signaling cascades as drug targets in model and pathogenic fungi.

Authors:  Robert J Bastidas; Jennifer L Reedy; Helena Morales-Johansson; Joseph Heitman; Maria E Cardenas
Journal:  Curr Opin Investig Drugs       Date:  2008-08

9.  Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis.

Authors:  Russell E Lewis; Ronen Ben-Ami; Leyla Best; Nathaniel Albert; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal:  J Infect Dis       Date:  2012-12-13       Impact factor: 5.226

10.  Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?

Authors:  Rafael Zaragoza; Javier Pemán; Miguel Salavert; Angel Viudes; Amparo Solé; Isidro Jarque; Emilio Monte; Eva Romá; Emilia Cantón
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.